In case you missed the testimony of Mylan's CEO Heather Bresch, you can see a replay via CSPAN.org. One of the items talked about during the testimony is the availability of generic Epipen. Ms. Bresch indicated that it would be the same product as the Epipen (from transcript of video on CSPAN - at about 30:53 on the video):

NIAID is seeking public comment on a draft update to the Guidelines for the Diagnosis and Management of Food Allergy in the United States to address the prevention of peanut allergy. Read the draft here and offer your input by Monday, April 18.